Opioids Compromise Effectiveness of Treatments for Alcohol Dependence
New research indicates that opioid misuse and the use of cannabis and other drugs may compromise the effectiveness of treatments for alcohol use disorder. In an Alcoholism: Clinical and Experimental Research study, individuals with alcohol dependence who misused opioids and those who used cannabis and other drugs were more likely to drink heavily and frequently during and following treatment.
On average, individuals with opioid misuse engaged in heavy drinking 48 days earlier in treatment, drank heavily on approximately 8% and 13% more days in the last month of treatment and one year following treatment, respectively, and consumed 4 more drinks per peak drinking occasion than individuals without opioid misuse and no other drug use.
"This study provides evidence that we cannot ignore alcohol and other drug use when discussing potential impacts of the opioid epidemic," said lead author Dr. Katie Witkiewitz, of the University of New Mexico. Individuals who misuse opioids have poorer outcomes in multiple domains, and the current study identified a much higher risk of alcohol relapse among those with opioid misuse in alcohol treatment."
This article has been republished from materials provided by Wiley. Note: material may have been edited for length and content. For further information, please contact the cited source.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE